-- SPARC AI Inc (SPAI.CN) 週一宣布，已與第二家烏克蘭無人機製造商簽署協議，將其納入 Overwatch 平台，這標誌著該公司的無 GPS 導航和精確目標定位軟體「持續保持商業成長勢頭」。 該公司表示，該協議獨立於先前宣布的烏克蘭合作夥伴關係，並為其在「全球要求最嚴苛」的電子戰環境中開闢了第二個分銷管道。 該公司表示：“每新增一家製造商，都會擴大公司的用戶基礎，並深化其專有機器學習模型的運行數據。” 該公司補充說，所有 Overwatch 部署仍需遵守適用的出口管制和國防貿易合規要求。 該公司表示：“SPARC AI 的市場策略旨在將 Overwatch 作為標準基礎設施嵌入到無人機和機器人平台中。在烏克蘭獲得第二家獨立製造商的支持，既驗證了市場對公司純軟體解決方案的需求，也驗證了其分銷模式的可複制性。” 該公司股票在加拿大證券交易所的最新報收於 3.26 美元，上漲 0.44 美元。
Price: $3.20, Change: $+0.38, Percent Change: +13.48%
Canada reports gross domestic product for February and the preliminary estimate for March on Thursday, said Scotiabank.February was initially guided by Statistics Canada to have been tracking a 0.2% month-over-month gain last month. Updated estimates are still in the same ballpark, but investors also get important details on sector drivers, noted the bank.More meaningful may be the flash guidance, with no details, for March GDP, for which there is very little information so far, but a small gain is "feasible," stated Scotiabank.The outcome will further inform Q1 GDP growth tracking on a production/income basis using monthly GDP. It's feasible that growth is tracking close to the Bank of Canada's 1.8% January Monetary Policy Report estimate, but that's on an expenditure basis. The massive over 4% inventory drag on Q4 GDP could reverse as an added upside, pointed out the bank.One key is that consumer spending on goods is tracking a strong rebound in Q1 based on retail sales volumes. It's untrue that the economy isn't exhibiting rate sensitivity, a view that is disproportionately driven by a false understanding of what's keeping condo markets weak in Toronto and Vancouver, added Scotiabank.
Alvaro Doyle, Vice President and Chief Information Officer, on April 23, 2026, sold 8,000 shares in Vicor (VICR) for $2,079,226. Following the Form 4 filing with the SEC, Doyle has control over a total of 42 common shares of the company, with 42 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/751978/000182673026000002/xslF345X05/primary_doc.xmlPrice: $265.29, Change: $-8.24, Percent Change: -3.01%
BioMarin Pharmaceutical (BMRN) is emerging as a broader rare-disease platform as its acquisition of Amicus Therapeutics (FOLD) adds two approved medicines and reduces reliance on Voxzogo, Morgan Stanley said Monday in a report.The Amicus deal reshapes BioMarin's outlook by adding Galafold and Pombiliti with Opfolda, products that fit the company's global commercial network, the report said. The therapies are expected to generate more than $1.3 billion in revenue by 2030, Morgan Stanley said.The acquisition is projected to accelerate revenue growth immediately after closing and to be accretive to non-GAAP earnings within 12 months, with "substantial accretion" beginning in 2027, the report said. BioMarin closed its $4.8 billion purchase of Amicus on Monday.Morgan Stanley resumed coverage on BioMarin stock with an overweight rating and a $120 price target.Price: $54.08, Change: $+0.90, Percent Change: +1.68%